MoffettNathanson analyst Craig Moffett upgrades AT&T (NYSE:T) from Sell to Neutral and raises the price target from $23 to $28.
Awakn Enters U.S. Addiction Treatment & Relapse Prevention Market With Ketamine Therapy For Alcohol Use Disorder
Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company focused on addiction treatments, has signed a licensing partnership agreement with US ketamine therapy clinics owner Revitalist Lifestyle and Wellness Ltd.